Dr. Singh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3805b Spring St
Suite 140
Racine, WI 53405Phone+1 262-637-8835Fax+1 262-635-8027
Education & Training
- Cook County Health and Hospitals SystemResidency, Ophthalmology, 2000 - 2003
- Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1999
Certifications & Licensure
- WI State Medical License 2004 - 2025
- IL State Medical License 2002 - 2008
- NC State Medical License 2003 - 2004
- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Medflow EHR, Medflow, Inc., 2012-2013
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery Start of enrollment: 2011 Dec 22
- Hydrus® Microstent New Enrollment Post-Approval Study Start of enrollment: 2020 Aug 25
Publications & Presentations
PubMed
- Safety and efficacy of travoprost intracameral implant administered in combination with cataract surgery.Inder Paul Singh, Lilit A Voskanyan, Kevin M Barber, James H Burden, LeAnne Connolly
Therapeutic Advances in Ophthalmology. 2025-02-14 - An Emerging Multi-mechanism and Multi-modal Approach in Interventional Glaucoma Therapy.J Morgan Micheletti, Mitchell Shultz, Inder Paul Singh, Thomas W Samuelson
Ophthalmology and Therapy. 2025-01-01 - A Randomized Controlled Trial Comparing STREAMLINE Canaloplasty to Trabecular Micro-Bypass Stent Implantation in Primary Open-Angle Glaucoma.Damien F Goldberg, Claudio Orlich, Brian E Flowers, Inder P Singh, Sydney Tyson
Clinical Ophthalmology. 2024-01-01
Press Mentions
- Seonix Bio Launches SightScore, the First Clinical Polygenic Risk Score Test for Glaucoma in the USFebruary 20th, 2025
- Alcon Announces US Launch of Voyager DSLT for Glaucoma and Ocular HypertensionFebruary 19th, 2025
- Alcon Announces U.S. Launch of Voyager DSLT, First-of-Its-Kind Treatment for Glaucoma and Ocular HypertensionFebruary 19th, 2025
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: